Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 ...

The atypical teratoid/rhabdoid tumor market growth is driven by rising molecular diagnosis and increased awareness of this aggressive pediatric CNS cancer, which is expanding the pool of identified ...

What is atypical, however, is how opponents hit just .216 against it, despite its average velocity of 93.3 mph. His ground ball percentage is also solid, sitting at 42.8, which is very good ...

The stock market is running high. Too high, some analysts say. A number of Wall Street observers warn the stock market may have entered "bubble" territory. It’s an analogy to the overhyped markets of ...

"Chronic Myelomonocytic Leukemia Pipeline 2025"DelveInsight's,“Chronic Myelomonocytic Leukemia - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline ...